Is This Pharmaceutical Giant a Winning Tariff-Proof Stock to Buy for 2026?

Company Overview - Novartis (NVS) is a pharmaceutical giant with a market capitalization of $310.8 billion, focusing on oncology, immunology, neuroscience, and more [1][9] - Notable products include Entresto, Cosentyx, Kesimpta, and Kisqali [1] Stock Performance - NVS shares have increased nearly 50% over the past 52 weeks and reached an all-time high of $148.38 on January 26 [5][6] - The stock has a 100% "Buy" technical opinion from Barchart and has gained 6.61% over the past month [5][6] - Since a new "Buy" signal was issued on December 2, shares are up 11.23% [2] Technical Indicators - NVS has a Weighted Alpha of +45.01 and a Relative Strength Index (RSI) of 73.14 [6] - The stock's 50-day moving average is $136.10, with a technical support level around $145.57 [6][7] Analyst Sentiment - Analysts expect earnings to increase by 13.32% in 2025 and another 2.94% in 2026 [9] - The stock has a trailing price-earnings ratio of 16.24x, with price targets ranging from $112 to $162.50 [9] - Short interest is very low at just 0.28% of the float [9]